The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.org Editorial Board led by Kim A. Eagle, MD, MACC.
OCEAN(a) DOSE: Does Olpasiran Reduce Lp(a) Concentrations in Patients With ASCVD
Olpasiran therapy significantly reduced lipoprotein(a) (Lp[a]) concentrations in patients with established atherosclerotic cardiovascular disease (ASCVD), based on findings from the OCEAN(a) DOSE trial presented at AHA 2022 and simultaneously published in the New England Journal of Medicine.
EMPA-KIDNEY: Meta-Analysis Highlights Benefits, Safety of SGLT2is in CKD or HF, Regardless of Diabetes
SGLT2 inhibitors safely reduce the risk of kidney disease progression, acute kidney injury, cardiovascular death, and hospitalization for heart failure (HF) in patients with chronic kidney disease (CKD) or HF, irrespective of diabetes status, according to results from the EMPA-KIDNEY meta-analysis presented at AHA 2022 and published in the New England Journal of Medicine.
BrigHtn: Baxdrostat to Reduce BP in Patients With Treatment-Resistant Hypertension
Baxdrostat significantly and substantially reduced systolic and diastolic blood pressure (BP) in patients with treatment-resistant hypertension, based on findings from the BrigHtn study presented at AHA 2022 and simultaneously published in the New England Journal of Medicine.
STRESS: Methylprednisolone in Infants Undergoing Cardiopulmonary Bypass Heart Surgery
Prophylactic use of methylprednisolone in infants undergoing cardiopulmonary bypass heart surgery did not improve postoperative outcomes compared with placebo, according to results from the STRESS trial presented at AHA 2022 and published in the New England Journal of Medicine. Additionally, prophylactic methylprednisolone was associated with postoperative development of hyperglycemia warranting insulin in a higher percentage of infants, researchers said.
Clinical Topics: Cardiac Surgery, Congenital Heart Disease and Pediatric Cardiology, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Vascular Medicine, Cardiac Surgery and CHD and Pediatrics, Cardiac Surgery and Heart Failure, Congenital Heart Disease, CHD and Pediatrics and Interventions, CHD and Pediatrics and Prevention, Acute Heart Failure, Pulmonary Hypertension, Interventions and Structural Heart Disease, Interventions and Vascular Medicine, Hypertension
Keywords: ACC Publications, Cardiology Magazine, Dyslipidemias, Metabolic Syndrome, Heart Failure, Hypertension, Pulmonary, AHA Annual Scientific Sessions, AHA22, Cardiac Surgical Procedures, Cardiac Surgical Procedures, Heart Defects, Congenital
< Back to Listings